Table 2 Summary of clinical trials with MSCs in treating multiple sclerosis
Clinical trial identifier | Clinical phase | Source | Registration year | Country | Clinical types in MS | Estimated number of MS patients | Primary evaluation after cell therapy | Ref./Completion year |
|---|---|---|---|---|---|---|---|---|
NCT01730547 | I/II | Autologous BM-MSCs | 2012 | Sweden | RRMS/SPMS/ PPMS | 15 | To assess the safety of IV therapy with autologous MSCs in MS patients | [178] |
NCT01854957 | I/II | Autologous MSCs | 2013 | Italy | Active MS | 20 | 1.Safety (Incidence and severity of adverse events 2.efficacy (total number of contrast-enhancinglesions (GEL) at MRI scan) | [178] |
NCT01606215 | I/II | Autologous MSCs | 2013 | UK | Active MS | 13 | check the procedure is safe and to measure any changes on the MRI at 24 weeks | [178] |
NCT02403947 | I/II | Autologous BM-MSCs | 2015 | France | MS | 12 | Efficacy assessed by combined unique magnetic resonance imaging (MRI) activity, volume of GEL, and volume of BH (black holes) | [178] |
NCT02035514 | I/II | Autologous BM-MSCs | 2013 | Spain | RRMS | 8 | Safety and Cumulative number of MRI Gd-enhancing lesions | [178] |
NCT00813969 | I | Autologous MSCs | 2011 | USA | RMS | 24 | To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS | [179] |
NCT02166021 | II | Autologous BM-MSCs | 2014 | Israel | Active progressive MS | 36 | To evaluate brain MRI and Immunological Response | [169] |
NCT00395200 | I/II | Autologous BM-MSCs | 2006 | UK | MS | 20 | Establish the safety by monitoring adverse reactions | (180) |
NCT00781872 | I/II | Autologous BM-MSCs | 2006 | Not Provided | MS | 20 | Safety and migration ability of the injected cells, clinical efficacy | [181] |
NCT00014755 | I | Autologous BM-MSCs | 2001 | USA | MS | 35 | To evaluate brain MRI, CSF, Long-term complications and survival | [182] |
NCT01056471 | I/II | Autologous AD-MSCs | 2011 | Spain | SPMS | 30 | Infusion of autologous AD-MSCs is safe and feasible in patients with SPMS | [183] |
NCT03326505 | I/II | Allogenic UC-MSCs | 2017 | Jordan | MS | 60 | The number, intensity and volume of CNS lesions will be assessed to investigate the therapeutic benefits of the injected Allogenic MSCs and/or Physical therapy by MRI | [184] |
NCT02034188 | I/II | Allogenic UC-MSCs | 2014 | Panama | MS | 20 | No serious adverse events were reported. MRI scans of the brain and the cervical spinal cord showed inactive lesions in 15/18 (83.3%) subjects after 1Â year | [185] |
NCT01377870 | I/II | Autologous BM-MSCs | 2011 | Iran | RRMS | 30 | Evaluate the effect of MSC transplantation on number of Gd(gadolinium) positive lesions | 2014 |
NCT01895439 | I/IIA | Autologous BM-MSCs | 2013 | Jordan | MS | 30 | By Magnetic Resonance Imaging (MRI) and ophthalmological tests | 2017 |
NCT02239393 | II | Autologous MSCs | 2014 | Canada | RRMS/SPMS/PPMS | 40 | 1.Safety (Incidence and severity of adverse events 2.efficacy (total number of contrast-enhancinglesions (GEL) at MRI scan) | 2014 |
NCT01056471 | I/II | Autologous AD- MSCs | 2010 | Spain | SPMS | 30 | To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells | 2015 |
NCT00017628 | I | Autologous MSCs | 2001 | USA | MS | 20 | MSC therapy is safe without side effects after injection | 2005 |
NCT03069170 | I | Autologous BM-MSCs | 2017 | Jordan | RRMS | 50 | Effectiveness assessment by MRI Safety assessment by physical examination,vitalsigns,analytical results,electrocardiograph monitoring, and EDSS | Unknown |
NCT02495766 | I/II | Autologous BM-MSCs | 2015 | Spain | RRMS/SPMS | 8 | MS therapy is safe without side effects after cell injection. Evaluated EDSS score | 2018 |
NCT02157064 | Not specified | Autologous AD-MSCs | 2014 | USA | MS | 100 | Change from Baseline on the Multiple Sclerosis Quality of Life Inventory (MSQLI) at 12Â months | Unknown |
NCT01364246 | I/II | Allogenic UC-MSCs | 2010 | China | Progressive MS | 20 | Evaluated core of EDSS, VEP (visual evoked potential), MRI, SEP (somatosensory evoked potential) and BAEP (brainstem auditory evoked potential). No side effects were apparent after cell injection | 2014 |